The Economics of Nicotinamide for Keratinocyte Carcinoma Prevention: What Does the Evidence (Not) Support? [0.03%]
烟酰胺预防角质细胞癌的经济学：证据（不）支持什么？
Ivo Abraham,Adewole S Adamson,Howa Yeung
Ivo Abraham
Joachim Hübner,Laura Schumann,Nora Eisemann et al.
Joachim Hübner et al.
Importance: In Germany, a population-based skin cancer screening (SCS) program was implemented in 2008. The benefit of the intervention is unclear. Object...
Madeline Sage,Christopher J Sayed
Madeline Sage
Cost-Effectiveness of Oral Nicotinamide for Keratinocyte Carcinoma Prevention [0.03%]
口服烟酰胺预防角质细胞癌的成本效益分析
David Perez,Kimberly F Breglio,Katlyn M Knox et al.
David Perez et al.
Importance: Keratinocyte carcinoma (KC) is the most common cancer in the US, resulting in considerable clinical and economic burdens. Nicotinamide has been shown to reduce new KCs among high-risk patients. Despite growing...
Yihang Xie,Xin Zeng,Xuefeng Zhang
Yihang Xie
Ecthymalike Ulcerations in Patients With Lung Cancer Treated With Combined Amivantamab and Osimertinib [0.03%]
氨磺必利和奥希替尼联合治疗肺癌患者的类蜂窝织炎性溃疡
Stephen Li,Yoo Jung Kim,Esther Choi et al.
Stephen Li et al.
Limits of Artificial Intelligence Models for Skin Cancer Diagnosis in Realistic Settings [0.03%]
人工智能模型在现实环境中进行皮肤癌诊断的局限性
Julien Anriot,Siyuan Yan,Clio Coste et al.
Julien Anriot et al.
Importance: Artificial intelligence (AI) systems for skin cancer detection perform well in controlled settings but frequently underperform in everyday clinical practice, raising critical questions about their readiness fo...
Error in Methods [0.03%]
方法错误
Published Erratum
JAMA dermatology. 2026 Jun 3:e261846. DOI:10.1001/jamadermatol.2026.1846 2026
Risk of Immunologic Reactions During Monthly Therapy for Hansen Disease [0.03%]
月复一个月利福平治疗期间免疫反应的风险评估研究:Hansen病患者登记数据报告
Peyton V Warp,Minsoo Kim,Kimberly Williams et al.
Peyton V Warp et al.
Soo Hyun Kim,Shelley McCormick,Hensin Tsao
Soo Hyun Kim